Reducing sensory eye dominance with learning protocol

Article

A recent study revealed a novel push-pull training protocol that was designed to reduce sensory eye dominance (SED).

A recent study, published in Current Biology, revealed a novel push-pull training protocol that was designed to reduce sensory eye dominance (SED), which is mainly caused by unbalanced interocular inhibition.

The training involved a cue that stimulated the weak eye (push) while causing interocular inhibition of the strong eye (pull). It was found that the protocol reduced SED and improved stereopsis better than the push only protocol, which only stimulates the weak eye without inhibiting the strong eye.

Additionally, it was indicated in the study that the design of this protocol could be used as a non-invasive treatment of amblyopia.

If you would like to learn more please click here

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.